Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for ...

The bladder cancer test developer says it will go to court if an unfavourable US reimbursement decision is not reversed.

· Tempus AI, Inc. (NASDAQ: TEM) started 2025 announcing the National Launch of its FDA -approved xT CDx Test, a 648-gene next-generation sequencing test for solid tumor profiling, which includes ...

A new report dives into the evolving clinical trial landscape and transformative therapies changing lives for bladder cancer ...

Disitamab vedotin is under clinical development by Pfizer and currently in Phase II for Metastatic ... HER2 expressing non-small cell lung cancer, non-muscle invasive bladder cancer (NMIBC), penile ...

Pfizer also has high hopes for PD-1/PD-L1 inhibitor sasanlimab for non-muscle invasive bladder cancer in the CREST study, and CD3xBCMA bispecific Elrexfio (elranatamab) in MagnetisMM-5 as a ...

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC ... web editor Nicole Raleigh sat down with Pfizer’s head of predictive analytics, Jonathan Crowther ...

Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that the first set of abstracts have been released from several studies that will be shared at the American Society ...

Pfizer (PFE) colorectal cancer therapy Braftovi as part of a drug combo indicates a favorable objective response rate in a ...

Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...

Pfizer Inc. (PFE) announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with ...